Relievant Medsystems Announces Highest Quality of Evidence Ranking for Basivertebral Nerve Ablation in ASPN Back Guideline for Interventional Low Back Pain Treatments

Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that basivertebral nerve (BVN) ablation received a Grade A Quality of Evidence Ranking with High Level of Certainty Regarding Net Benefit in the American Society of Pain & Neuroscience (ASPN) Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain. The publication is the most comprehensive analysis and grading of existing and emerging interventional treatments available for low back pain and was published in Volume 15 of the Journal of Pain Research.

The ASPN Back Guideline was developed to provide clinicians with the most comprehensive review of interventional treatments for lower back disorders and established a therapy grade – including level of evidence and level of certainty net benefit – for the most commonly available interventional treatments. BVN ablation attained the highest possible marks in both areas, including a Grade A Quality of Evidence Ranking and High Level of Certainty Regarding Net Benefit. The ASPN Back Group recommends BVN ablation with “high certainty that the net benefit is substantial”, noting that the evidence includes consistent treatment results from well-designed, well-conducted studies and that future studies would be unlikely to affect this conclusion.

“We are pleased to see BVN ablation recognized as having the highest quality of evidence and level of certainty regarding treatment benefit in this comprehensive, collaborative, and multi-specialty analysis,” said Tyler Binney, President and CEO of Relievant Medsystems. “The ASPN Back Guideline is the latest in a series of society-driven clinical guidelines that validate BVN ablation treatment such as the Intracept® Procedure in helping patients find relief from their chronic vertebrogenic low back pain.”

Relievant Medsystems’ minimally invasive Intracept® Procedure is the only FDA-cleared treatment for chronic vertebrogenic low back pain, using targeted radiofrequency energy to stop the BVN from transmitting pain signals to the brain. The procedure is typically performed in an outpatient surgery center and takes approximately one hour. Based on existing data, patients typically experience minimal post-procedure pain and generally quick recovery times. Patients often feel pain relief within two weeks of being treated with the Intracept Procedure.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy